LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Inicio・Lista de Acciones・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Cerrado

SectorSalud

43.05 1.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

43.05

Máximo

43.05

Métricas clave
By Trading Economics
Ingresos	-6.2M -91M
Margen de beneficio	-867.293
Empleados	316
EBITDA	4M -90M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+27.67% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-25M 3.2B
Apertura anterior	41.4
Cierre anterior	43.05

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

49 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

34.81 / 38.24 Soporte y Resistencia

Xenon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 feb 2026, 17:37 UTC

Adquisiciones, fusiones, absorciones

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20 feb 2026, 16:18 UTC

Principales Movimientos del Mercado

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20 feb 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Ganancias

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Ganancias

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Charlas de Mercado

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Adquisiciones, fusiones, absorciones

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20 feb 2026, 20:17 UTC

Charlas de Mercado

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20 feb 2026, 20:11 UTC

Charlas de Mercado

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20 feb 2026, 19:59 UTC

Charlas de Mercado

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20 feb 2026, 19:58 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20 feb 2026, 19:49 UTC

Charlas de Mercado

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20 feb 2026, 19:09 UTC

Charlas de Mercado

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20 feb 2026, 19:00 UTC

Charlas de Mercado

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20 feb 2026, 18:28 UTC

Charlas de Mercado

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20 feb 2026, 18:20 UTC

Charlas de Mercado

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20 feb 2026, 18:05 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 18:04 UTC

Charlas de Mercado

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20 feb 2026, 17:38 UTC

Charlas de Mercado

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Correction to Treasury Yields Fall Market Talk

20 feb 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

20 feb 2026, 16:53 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 16:53 UTC

Charlas de Mercado

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20 feb 2026, 16:40 UTC

Charlas de Mercado

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

27.67% repunte

Estimación a 12 meses

Media 55 USD 27.67%

Máximo 66 USD

Mínimo 44 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

49 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.